BRPI0814432A2 - pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc - Google Patents
pirimidinadiaminas substituídas por amina cíclica como inibidores de pkcInfo
- Publication number
- BRPI0814432A2 BRPI0814432A2 BRPI0814432A BRPI0814432A BRPI0814432A2 BR PI0814432 A2 BRPI0814432 A2 BR PI0814432A2 BR PI0814432 A BRPI0814432 A BR PI0814432A BR PI0814432 A BRPI0814432 A BR PI0814432A BR PI0814432 A2 BRPI0814432 A2 BR PI0814432A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidinadiamines
- cyclic amine
- amine substituted
- pkc inhibitors
- pkc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95030907P | 2007-07-17 | 2007-07-17 | |
US98518407P | 2007-11-02 | 2007-11-02 | |
US4975008P | 2008-05-01 | 2008-05-01 | |
PCT/US2008/070387 WO2009012421A1 (en) | 2007-07-17 | 2008-07-17 | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0814432A2 true BRPI0814432A2 (pt) | 2017-05-09 |
Family
ID=39830300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0814432A BRPI0814432A2 (pt) | 2007-07-17 | 2008-07-17 | pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc |
Country Status (11)
Country | Link |
---|---|
US (1) | US8993585B2 (pt) |
EP (1) | EP2183225A1 (pt) |
JP (1) | JP5586460B2 (pt) |
KR (1) | KR20100049068A (pt) |
CN (1) | CN101903357A (pt) |
AU (1) | AU2008275918B2 (pt) |
BR (1) | BRPI0814432A2 (pt) |
CA (1) | CA2693594A1 (pt) |
IL (1) | IL203193A (pt) |
NZ (1) | NZ582485A (pt) |
WO (1) | WO2009012421A1 (pt) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
ES2421139T3 (es) * | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
JP5225079B2 (ja) | 2005-06-08 | 2013-07-03 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jak経路の阻害のための組成物および方法 |
CA2673125C (en) | 2006-10-19 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP2420505A1 (en) | 2006-11-21 | 2012-02-22 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses |
US7834024B2 (en) * | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
JP5586482B2 (ja) * | 2008-02-22 | 2014-09-10 | ライジェル ファーマシューティカルズ, インコーポレイテッド | アテローム性動脈硬化症の治療のための2,4−ピリミジンジアミンの使用 |
EP3210609A1 (en) | 2008-05-21 | 2017-08-30 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
CA2986640C (en) | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AU2013202496B2 (en) * | 2008-06-27 | 2016-08-04 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
MX2011002306A (es) * | 2008-09-01 | 2011-05-25 | Astellas Pharma Inc | Compuesto de 2,4-diaminopirimidina. |
EP2341052A4 (en) * | 2008-09-05 | 2011-10-12 | Shionogi & Co | RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT |
WO2010083240A2 (en) * | 2009-01-14 | 2010-07-22 | Rigel Pharmaceuticals, Inc. | Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds |
ES2555982T3 (es) * | 2009-01-15 | 2016-01-12 | Rigel Pharmaceuticals, Inc. | Inhibidores de la proteína quinasa C y usos de los mismos |
JP5781943B2 (ja) * | 2009-01-21 | 2015-09-24 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なn2−(3−ピリジルまたはフェニル)−n4−(4−ピペリジル)−2,4−ピリミジンジアミン誘導体 |
CA2760794C (en) | 2009-05-05 | 2017-07-25 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
CN102421761B (zh) | 2009-05-08 | 2014-06-18 | 安斯泰来制药株式会社 | 二氨基杂环甲酰胺化合物 |
JP2012148977A (ja) * | 2009-05-20 | 2012-08-09 | Astellas Pharma Inc | アミノシクロヘキシルアルキル基を有する2,4−ジアミノピリミジン化合物 |
BR112012002001A2 (pt) * | 2009-07-28 | 2016-05-10 | Rigel Pharmaceuticals Inc | método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit |
EP2464633A1 (en) | 2009-08-14 | 2012-06-20 | Boehringer Ingelheim International GmbH | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
CA2780759A1 (en) * | 2009-12-01 | 2011-06-09 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
US20110142814A1 (en) * | 2009-12-16 | 2011-06-16 | New York University | Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy |
WO2011075560A1 (en) | 2009-12-17 | 2011-06-23 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
GEP20146125B (en) | 2009-12-17 | 2014-07-25 | Merck Canada | Aminopyrimidines as syk inhibitors |
JP5713367B2 (ja) | 2010-06-04 | 2015-05-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Lrrk2モジュレーターとしてのアミノピリミジン誘導体 |
EP2595982B1 (en) * | 2010-07-21 | 2018-06-13 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
KR20130099040A (ko) | 2010-08-10 | 2013-09-05 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Btk 억제제의 베실레이트 염 |
EP2635285B1 (en) | 2010-11-01 | 2017-05-03 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US8975249B2 (en) | 2010-11-01 | 2015-03-10 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
BR112013011600B1 (pt) | 2010-11-10 | 2022-01-11 | Genentech, Inc | Derivados de pirazol aminopirimidina, seu uso e composição que os compreende |
US8796255B2 (en) | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
KR102055532B1 (ko) | 2011-04-22 | 2019-12-12 | 시그날 파마소티칼 엘엘씨 | 치환된 디아미노카르복스아미드 및 디아미노카르보니트릴 피리미딘, 그의 조성물, 및 그를 사용하는 치료 방법 |
BR112013027734A2 (pt) | 2011-05-04 | 2017-08-08 | Ariad Pharma Inc | compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica |
WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
WO2012154520A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
EP2706853B1 (en) | 2011-05-10 | 2017-06-14 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
CA2853498A1 (en) | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
RS57901B1 (sr) | 2012-03-15 | 2019-01-31 | Celgene Car Llc | Soli inhibitora kinaze receptora epidermalnog faktora rasta |
EP2825041B1 (en) | 2012-03-15 | 2021-04-21 | Celgene CAR LLC | Solid forms of an epidermal growth factor receptor kinase inhibitor |
EP2833889B1 (en) * | 2012-04-04 | 2017-11-01 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
EP2935226A4 (en) | 2012-12-21 | 2016-11-02 | Celgene Avilomics Res Inc | HETEROARYL COMPOUNDS AND USES THEREOF |
PE20151274A1 (es) | 2013-02-08 | 2015-09-12 | Celgene Avilomics Res Inc | Inhibidores de erk y sus usos |
US9169249B2 (en) | 2013-03-14 | 2015-10-27 | Rigel Pharmaceuticals, Inc. | Protein kinase C inhibitors and uses thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
WO2015039613A1 (zh) * | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
MX2016012574A (es) | 2014-03-28 | 2017-09-26 | Calitor Sciences Llc | Compuestos heteroarilo sustituidos y metodos de uso. |
US10300058B2 (en) | 2014-04-18 | 2019-05-28 | Xuanzhu Pharma Co., Ltd. | Tyrosine kinase inhibitor and uses thereof |
ES2741785T3 (es) | 2014-08-13 | 2020-02-12 | Celgene Car Llc | Formas y composiciones de un inhibidor de ERK |
WO2016060963A1 (en) * | 2014-10-14 | 2016-04-21 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
ES2882954T3 (es) | 2014-12-16 | 2021-12-03 | Signal Pharm Llc | Usos médicos que comprenden métodos para la medición de la inhibición de la quinasa c-Jun N-terminal en la piel |
US9796685B2 (en) | 2014-12-16 | 2017-10-24 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide |
EP3250557A4 (en) | 2015-01-29 | 2018-06-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
US10045985B2 (en) * | 2015-07-09 | 2018-08-14 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
WO2017019487A1 (en) | 2015-07-24 | 2017-02-02 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
WO2017017004A1 (en) * | 2015-07-24 | 2017-02-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Substituted hydrophobic benzene sulfonamide thiazole compounds for use in treating cancer |
US10336734B2 (en) | 2015-08-02 | 2019-07-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of ACK1/TNK2 tyrosine kinase |
CN106397432B (zh) * | 2015-08-03 | 2018-03-16 | 南昌弘益科技有限公司 | 作为jak抑制剂的一类化合物 |
EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
JP7065840B2 (ja) | 2016-06-27 | 2022-05-12 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4-ジアミノ-ピリミジン化合物ならびに該化合物の作製法および使用法 |
KR20190092542A (ko) * | 2016-12-19 | 2019-08-07 | 에피자임, 인코포레이티드 | Ehmt2 저해제로서의 아민-치환된 헤테로사이클릭 화합물 및 이의 사용 방법 |
CN106727584A (zh) * | 2017-02-08 | 2017-05-31 | 于贵庆 | 一种治疗骨病的药物组合物 |
CA3060416A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
EP3670500A4 (en) * | 2017-08-18 | 2020-12-16 | Beijing Hanmi Pharmaceutical Co., Ltd. | CHEMICAL COMPOUND, PHARMACEUTICAL COMPOSITION OF IT, CORRESPONDING USE AND APPLICATION |
WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
EP3788033A1 (en) * | 2018-05-04 | 2021-03-10 | Portola Pharmaceuticals, Inc. | Synthesis of cerdulatinib |
US20230124361A1 (en) * | 2020-02-12 | 2023-04-20 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
WO2023244775A1 (en) * | 2022-06-17 | 2023-12-21 | Boehringer Ingelheim Animal Health USA Inc. | Boron containing pyrimidine compounds, compositions comprising them, methods and uses thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US6492396B2 (en) | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
JP4510442B2 (ja) * | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | TNF−α発現のN−ヘテロ環インヒビター |
EP2332924A1 (de) | 2001-10-17 | 2011-06-15 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CA2489458A1 (en) | 2002-06-14 | 2003-12-24 | Altana Pharma Ag | Substituted diaminopyrimidines |
WO2004002964A1 (ja) * | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
NZ537752A (en) | 2002-07-29 | 2006-12-22 | Rigel Pharmaceuticals Inc | Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
SI1625121T1 (sl) | 2002-12-20 | 2010-04-30 | Pfizer Prod Inc | Derivati pirimidina za zdravljenje abnormalne rasti celic |
US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
CA2514612A1 (en) * | 2003-01-30 | 2004-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
ES2421139T3 (es) * | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
DE602004032446D1 (de) | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
EA200601796A1 (ru) * | 2004-05-14 | 2007-04-27 | Пфайзер Продактс, Инк. | Пиримидиновые производные для лечения аномального клеточного роста |
US20060058525A1 (en) | 2004-09-01 | 2006-03-16 | Rajinder Singh | Synthesis of 2,4-pyrimidinediamine compounds |
US7557207B2 (en) | 2004-11-24 | 2009-07-07 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
ES2337496T3 (es) | 2005-01-19 | 2010-04-26 | Rigel Pharmaceuticals, Inc. | Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos. |
WO2007027238A2 (en) | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
JP5225079B2 (ja) | 2005-06-08 | 2013-07-03 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jak経路の阻害のための組成物および方法 |
US7576053B2 (en) | 2005-06-13 | 2009-08-18 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
EP1951261A4 (en) | 2005-10-31 | 2009-06-24 | Rigel Pharmaceuticals Inc | PREPARATIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
AU2006309013B2 (en) | 2005-11-01 | 2012-06-28 | Impact Biomedicines, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US7713987B2 (en) | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
DE602006016861D1 (de) | 2005-12-21 | 2010-10-21 | Konarka Technologies Inc | Photovoltaische tandemzellen |
JP4332590B2 (ja) | 2005-12-21 | 2009-09-16 | ファイザー・プロダクツ・インク | 異常細胞増殖を治療するためのピリミジン誘導体 |
WO2007120980A2 (en) | 2006-02-17 | 2007-10-25 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
US20070293494A1 (en) * | 2006-06-15 | 2007-12-20 | Djung Jane F | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines |
CN101417966A (zh) | 2007-10-25 | 2009-04-29 | 北京天擎化工有限责任公司 | 3-异噻唑啉酮衍生物的连续式生产方法 |
JP2011506560A (ja) | 2007-12-20 | 2011-03-03 | ノバルティス アーゲー | Pi3キナーゼ阻害剤として用いられるチアゾール誘導体 |
-
2008
- 2008-07-17 CA CA2693594A patent/CA2693594A1/en not_active Abandoned
- 2008-07-17 US US12/175,441 patent/US8993585B2/en not_active Expired - Fee Related
- 2008-07-17 CN CN2008800249619A patent/CN101903357A/zh active Pending
- 2008-07-17 EP EP08782014A patent/EP2183225A1/en not_active Withdrawn
- 2008-07-17 JP JP2010517172A patent/JP5586460B2/ja not_active Expired - Fee Related
- 2008-07-17 KR KR1020107003268A patent/KR20100049068A/ko not_active Application Discontinuation
- 2008-07-17 NZ NZ582485A patent/NZ582485A/xx not_active IP Right Cessation
- 2008-07-17 AU AU2008275918A patent/AU2008275918B2/en not_active Ceased
- 2008-07-17 BR BRPI0814432A patent/BRPI0814432A2/pt not_active IP Right Cessation
- 2008-07-17 WO PCT/US2008/070387 patent/WO2009012421A1/en active Application Filing
-
2010
- 2010-01-07 IL IL203193A patent/IL203193A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US8993585B2 (en) | 2015-03-31 |
EP2183225A1 (en) | 2010-05-12 |
AU2008275918A1 (en) | 2009-01-22 |
JP2010533733A (ja) | 2010-10-28 |
KR20100049068A (ko) | 2010-05-11 |
IL203193A (en) | 2015-05-31 |
WO2009012421A1 (en) | 2009-01-22 |
CA2693594A1 (en) | 2009-01-22 |
NZ582485A (en) | 2012-05-25 |
US20100130486A1 (en) | 2010-05-27 |
CN101903357A (zh) | 2010-12-01 |
JP5586460B2 (ja) | 2014-09-10 |
AU2008275918B2 (en) | 2014-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0814432A2 (pt) | pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc | |
CY2020023I2 (el) | Αναστολεiς βητα-λακταμασων | |
NO2023019I1 (no) | Dupilumab - forlenget SPC | |
CY2017016I1 (el) | Αναστολεις πρωτεασωματος | |
BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
BRPI0811639A2 (pt) | Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina | |
BRPI0811065A2 (pt) | Indazóis 5-heteroaril substituídos como inibidores de quinase | |
BRPI0812825A2 (pt) | Derivados ftalazinona como inibidores de parp-1 | |
BRPI0913544A2 (pt) | dispositivo de localização do espaço epidural | |
DK2340021T3 (da) | Substituerede pyrrolidin-2-carboxamider | |
BRPI0919818A2 (pt) | inibidores de seprase seletivos | |
DK2229572T3 (da) | Rekuperator | |
DE112009001515A5 (de) | Befestigungsbinder | |
DK2326651T3 (da) | Buprenorphinanaloger | |
BRPI0814797A2 (pt) | Inibidores dna-pk | |
BRPI0912475A8 (pt) | compostos como inibidores de quinase | |
BRPI0918064A2 (pt) | distribuidor de substância | |
BRPI0918564A2 (pt) | inibidores | |
BRPI0922466A2 (pt) | sais | |
AT506380A3 (de) | Stempelvorrichtung | |
BRPI0716532A2 (pt) | compostos azabicÍclios como inidores de reabsorÇço de monoaminas | |
BRPI0716198A2 (pt) | Pirrolo-isoquinolinas como inibidores de cinase | |
DK2240506T3 (da) | IAP inhibitorer | |
FI20090015A0 (fi) | Työkalun kiinnitysjärjestely |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |